Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Dual pathways of antibody-dependent phagocytosis: Distinct kinetics, finite capacities, and therapeutic implications

Carly Van Wagoner, Hanna Sovinski, Brett Ransegnola et al. Nov 03, 2025 pp. 2998-2998 10.1182/blood-2025-2998

Abstract Macrophage antibody dependent cellular phagocytosis (ADCP) is a major cytotoxic mechanism for therapeutic monoclonal antibodies (mA...

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with azacitidine and  Chidamide can be an effective chemotherapy regimen for patients with angioimmunoblastic T-cell lymphoma (AITL)

Yanli Wang, Xuliang Shen, Guoxiang Zhang et al. Nov 03, 2025 pp. 3652-3652 10.1182/blood-2025-3652

Abstract Background: Angioimmunoblastic T-cell lymphoma (AITL) originates from follicular helper T-cell (THF), is the second most common subt...

Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT

Jia Chen, Maud Ngoya, Depei Wu et al. Nov 03, 2025 pp. 2526-2526 10.1182/blood-2025-2526

Abstract Introduction T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive precursor lymphoid neoplasm that accounts for 20% to 25%...

Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma

Qian Wang, Jin Zhou, Yun Wang et al. Nov 03, 2025 pp. 3742-3742 10.1182/blood-2025-3742

Abstract Background Elderly patients often present with multiple comorbidities due to age-related decline in physiological function, leading...

Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma

Xiaoyi Zhang, Buse Eglenen Polat, Kimberly Seymour et al. Nov 03, 2025 pp. 7059-7059 10.1182/blood-2025-7059

Abstract Introduction. Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, rare malignancy with poor survival despite anthracycline-base...

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Arnon Nagler, Allain Thibeault Ferhat, Didier Blaise et al. Nov 03, 2025 pp. 4288-4288 10.1182/blood-2025-4288

Abstract Background: Allogeneic transplantation (HSCT) is a curative therapeutic option for high-risk AML. The results of HSCT are in correl...

Multi-omics reveals immune features in immune and non-immune cells, an IFN-γ/IFN-α-B2M positive feedback loop, and targeted metabolic therapy in multiple myeloma

Chen Li, Yaping Liao, Rongfang Wei et al. Nov 03, 2025 pp. 7450-7450 10.1182/blood-2025-7450

Abstract Introduction: Multiple myeloma (MM) remains incurable despite ongoing advancements in treatment, with the major...

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Fabian Müller, Nora Rebecca Schwingen, Anne Hartebrodt et al. Nov 03, 2025 pp. 4171-4171 10.1182/blood-2025-4171

Abstract Chimeric antigen receptor (CAR) T-cells have proven highly efficacious in the treatment of relapsed/refractory B-cell malignancies....

NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma

Anna Baj, Jonathan Patton, Robert Chavez et al. Nov 03, 2025 pp. 572-572 10.1182/blood-2025-572

Abstract Introduction: The t(4;14) translocation subtype of multiple myeloma (MM) is characterized by overexpression of NSD2, a histone meth...

Neutrophil subpopulation-specific ratio and neutrophil extracellular traps are dynamic and sensitive biomarkers of thrombo-inflammation in patients with acute coronary syndrome – a prospective study

Shirly Partouche, Roy Hershenson, Idan Goldberg et al. Nov 03, 2025 pp. 1217-1217 10.1182/blood-2025-1217

Abstract Neutrophils have recently emerged as important effectors of thrombo-inflammation that contribute to the initiation and progression...

First report of successful, lifesaving and timely graft rescue using an off-the-shelf cryopreserved, cadaveric marrow in myeloablative transplant with an unexpected unavailability of a living matched unrelated donor.

Sumithira Vasu, Nicole Szuminski, Sagar Munjal et al. Nov 03, 2025 pp. 7708-7708 10.1182/blood-2025-7708

Abstract BACKGROUND: Allogeneic hematopoietic cell transplantation (alloHCT) remains a curative therapy for patients with acute myeloid leuk...

The total blood n-glycome landscape of hematological malignancies

Yueyi Xu, Jue Wang, Junli Zhang et al. Nov 03, 2025 pp. 391-391 10.1182/blood-2025-391

Abstract Introduction Hematological malignancies (HM) are heterogeneous with complex pathophysiology. Glycans, the third major informational...

Alterations in the gut microbiome and the association of butyrate producers with progression-free survival in multiple myeloma patients undergoing autologous stem cell transplantation

Ariel Aptekmann, Enrique Corapi, Iriana Colorado et al. Nov 03, 2025 pp. 575-575 10.1182/blood-2025-575

Abstract Background: The gut microbiome and microbial metabolites are key predictors and modulators of tumorigenesis, anti-tumor immunity, a...

The use of danicopan as an add-on therapy in a ravulizumab-treated adult patient with paroxysmal nocturnal hemoglobinuria (PNH) and concomitant stage IV renal failure has induced a marked improvement of anemia and of clinically significant extravascular hemolysis in absence of deterioration of renal function

Francesco Lanza, Barbara Castagnari, Claudia Cellini et al. Nov 03, 2025 pp. 6446-6446 10.1182/blood-2025-6446

Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder characterized by chronic hemolytic anemia, thrombosis...

Persistent binding of DNMT1 to chromatin causes replication dysfunction in TP53-mutated myeloid neoplasms

Jeremy Baeten, Sumedha Agashe, Imène Tabet et al. Nov 03, 2025 pp. 5017-5017 10.1182/blood-2025-5017

Abstract Mutations in TP53 are the worst prognostic factor for myeloid malignancies, with a median survival of 6-9 months. Treatment with a...

Physical activity in patients undergoing hematopoietic stem cell transplantation

Lauren Waldman, Daniel Schaefer, Michelle Guo et al. Nov 03, 2025 pp. 6036-6036 10.1182/blood-2025-6036

Abstract Background: Hematopoietic stem cell transplant (HSCT) recipients experience a high physical and emotional symptom burden that can i...

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03)

Eric Huselton, Uma Borate, John Reagan et al. Nov 03, 2025 pp. 3466-3466 10.1182/blood-2025-3466

Abstract Background: Acute myeloid leukemia (AML) with an IDH2 mutation represents a distinct molecular subtype with sensitivity to venetocla...

Final results from the embolden trial:  pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma

Nathan Roberts, John Lister, N. Nora Bennani et al. Nov 03, 2025 pp. 5417-5417 10.1182/blood-2025-5417

Abstract Background: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis with median overall...

Association between extreme heat exposures and survival in patients with multiple myeloma

Thomas Kuczmarski, Qingyang Zhu, Yang Liu et al. Nov 03, 2025 pp. 2786-2786 10.1182/blood-2025-2786

Abstract Introduction Climate change has far-reaching health implications through a variety of exposure pathways, including heat stress from...

Real-world outcomes of sutimlimab in cold agglutinin disease: A multicenter trinetx analysis

Shanawar Waris, Muqtasid Khan, Nanda Siva et al. Nov 03, 2025 pp. 6256-6256 10.1182/blood-2025-6256

Abstract Background Cold Agglutinin Disease (CAD) is a rare autoimmune hemolytic anemia, caused by cold agglutinins (IgM autoantibodies) tha...

Targeting NLRP3 with ofirnoflast, alone or in combination with semaglutide, ameliorates inflammatory anemia associated with obesity-induced inflammation in rodent models

Benjamin Bearss, Jared Bearss, Chadwick Davis et al. Nov 03, 2025 pp. 1127-1127 10.1182/blood-2025-1127

Abstract Background: Inflammatory anemia is a common manifestation of chronic disease that arises when sustained cytokine-mediated inflammat...

The prognostic value for survival of frailty and patient-reported outcomes in relapsed/refractory multiple myeloma: Results from a prospective multicenter observational study

Fabio Efficace, Gianluca Gaidano, Pasquale Niscola et al. Nov 03, 2025 pp. 138-138 10.1182/blood-2025-138

Abstract Background Clinical decisions for patients with relapsed/refractory multiple myeloma (RRMM) are challenging and assessment of frail...

Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income

Leon Bernal-Mizrachi, Ruemu Birhiray, Murtaza Bhuriwala et al. Nov 03, 2025 pp. 4004-4004 10.1182/blood-2025-4004

Abstract Introduction: Prolonged parenteral treatment for multiple myeloma may expose patients (pts) to cumulative side effects that can sign...

Incidence of venous thromboembolism in transgender individuals on estrogen-based gender-affirming hormone therapy

Hayley Cunningham, Sofia Burgoon, Carly Kelley et al. Nov 03, 2025 pp. 313-313 10.1182/blood-2025-313

Abstract Background: Historically, the use of estrogen-based gender-affirming hormone therapy (E-GAHT) has been associat...

Hematopoietic stem cell transplantation in T-cell lymphomas: A promising strategy challenging poor prognosis

Mistral Castellanos Mares, Amaya Llorente-Chávez, Rodrigo Figueroa-Méndez et al. Nov 03, 2025 pp. 7151-7151 10.1182/blood-2025-7151

Abstract Introduction: T-cell lymphomas (TCLs) are a rare and aggressive entity, with a higher prevalence in Latin America and Asia. The mos...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page